Literature DB >> 1890140

Growth, ribonucleotide reductase and metals in murine leukemic lymphocytes.

M Oblender1, U Carpentieri.   

Abstract

Trace metals are essential for the growth and several other properties of human lymphocytes. We studied the effects of media with variable concentrations of three metals (Fe2+, Cu2+, Zn2+), a metal chelator (deferoxamine, DFX) and a cell-growth inhibitor (hydroxyurea) on the growth, intracellular metal concentration and activity of the enzyme ribonucleotide reductase in murine leukemic lymphocytes (L1210). Intracellular concentrations of Fe and Cu fluctuated within narrow limits in normal media, but decreased to very low concentrations in metal-poor media. The intracellular Zn concentration did not vary appreciably. Growth in intact cells decreased by 50%-70% when normal media were replaced by metal-poor media, but returned to control values when media were supplemented with gradually increasing concentrations of Fe and Cu. Fe and Cu had synergistic effects, while Zn had no stimulatory action. Hydroxyurea and DFX both inhibited cell growth, but only DFX inhibition was reversed by addition of metals. The addition of the above metals and inhibitors to the cell extracts produced effects on ribonucleotide reductase activity similar to those observed on the growth of whole cell preparations (stimulation by Fe and Cu, inhibition by Zn, DFX and hydroxyurea). These findings show that (a) the intracellular metal concentration is maintained in a narrow range during cell growth; (b) ribonucleotide reductase activity varies with cell growth; (c) ribonucleotide reductase activity and cell growth increase with Fe and Cu and decrease with Zn and DFX. Our data suggest that (a) Fe, Cu and Zn may have some effect on the growth and ribonucleotide reductase activity of L1210 cells, that (b) Fe, Cu and Zn may operate in a related and interdependent way and that (c) DFX inhibits cell growth probably through inhibition of the reductase activity and chelation of the Fe of its Fe-containing subunit. We conclude that any study on one of these metals should always include the other two and that manipulation of intracellular metals should be investigated as a potential therapeutic modulator of growth in leukemic lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890140     DOI: 10.1007/bf01612765

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

1.  Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies.

Authors:  L Dezza; M Cazzola; M Danova; C Carlo-Stella; G Bergamaschi; S Brugnatelli; R Invernizzi; G Mazzini; A Riccardi; E Ascari
Journal:  Leukemia       Date:  1989-02       Impact factor: 11.528

2.  Zinc can increase the activity of protein kinase C and contributes to its binding to plasma membranes in T lymphocytes.

Authors:  P Csermely; M Szamel; K Resch; J Somogyi
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

3.  In vitro leukemic cell differentiation in metal-depleted media.

Authors:  U Carpentieri; L W Thorpe
Journal:  Anticancer Res       Date:  1987 Mar-Apr       Impact factor: 2.480

4.  Heavy metal ions in transcription factors from HeLa cells: Sp1, but not octamer transcription factor requires zinc for DNA binding and for activator function.

Authors:  G Westin; W Schaffner
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

5.  Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells.

Authors:  C Kaplinsky; Z Estrov; M H Freedman; E W Gelfand; A Cohen
Journal:  Leukemia       Date:  1987-05       Impact factor: 11.528

6.  Ribonucleotide reductase and thymidine kinase activities in various cultured cell lines derived from hematologic malignancies.

Authors:  E Takeda; M Hirose; Y Kuroda; T Ninomiya; K Toshima; T Watanabe; M Ito; E Naito; M Miyao
Journal:  Gan       Date:  1984-09

7.  Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry.

Authors:  R C Whitehouse; A S Prasad; P I Rabbani; Z T Cossack
Journal:  Clin Chem       Date:  1982-03       Impact factor: 8.327

8.  Cytotoxicity of zinc in vitro.

Authors:  J Borovanský; P A Riley
Journal:  Chem Biol Interact       Date:  1989       Impact factor: 5.192

9.  Synthesis of acyclonucleoside hydroxamic acids as inhibitors of ribonucleotide reductase.

Authors:  R A Farr; P Bey; P S Sunkara; B J Lippert
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

10.  A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.

Authors:  D Veale; J Carmichael; B M Cantwell; H L Elford; R Blackie; D J Kerr; S B Kaye; A L Harris
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

View more
  1 in total

1.  Changes of CSF-Cu and -Zn in children with acute lymphoblastic leukemia.

Authors:  J P Van Wouwe; M H Van Weel-Sipman
Journal:  Biol Trace Elem Res       Date:  1993-09       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.